Published Studies Related to Betimol (Timolol Ophthalmic)
Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus
bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or
ocular hypertension: a 12-week randomised controlled trial. 
hypertension... CONCLUSIONS: Bimatoprost/timolol PF demonstrated non-inferiority and equivalence
Effect of timolol on refractive outcomes in eyes with myopic regression after
laser in situ keratomileusis: a prospective randomized clinical trial. 
(length 4 to 8) was used for treatment allocation... CONCLUSIONS: Timolol application is effective for the treatment of myopic
Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. [2011.09]
PURPOSE: The purpose of this study is to compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost/timolol in a benzalkonium chloride (BAK)-free fixed combination preserved with polyquaternium-1 (TRA/TIM BAK-free), with travoprost/timolol-fixed combination preserved with BAK (TRA/TIM), in patients with open-angle glaucoma or ocular hypertension... CONCLUSION: Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy. No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
BACKGROUND: To compare the efficacy and safety of timolol 0.5% versus brinzolamide 1.0% when added to travoprost monotherapy in patients with primary open-angle glaucoma or ocular hypertension... CONCLUSION: Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy, with timolol being slightly stronger 8 hours after instillation. Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost.
[Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension]. [2011.06]
CONCLUSION: MK-0507A has a significantly superior IOP-lowering effect relative to timolol. MK-0507A also showed a non-inferior IOP-lowering effect relative to the concomitant therapy. MK-0507A was safe compared to both timolol and concomitant therapy.
Clinical Trials Related to Betimol (Timolol Ophthalmic)
Timolol Option for Ulcerated Hemangiomas (TOUCH Trial) [Withdrawn]
The purpose of this study is to determine whether Timolol 0. 5% Gel Forming Solution is safe
and effective in promoting wound healing of infantile ulcerated hemangiomas compared with
standard conservative management with topical antibiotic.
Topical Timolol Benefit in Venous Ulcers [Not yet recruiting]
Background: Venous Leg ulcers are a frequent pathology in dermatology and complex in their
management. At the origin of high health costs and strong repercussions on quality of life
for patients, they require long management and may be subject to possible complications.
In spite of appropriate treatment, 50-60% of these ulcers are not healed at 24 weeks.
Purpose: Topical beta adrenergic antagonists have shown efficacy in wound healing. The
purpose of this study is to evaluate the efficacy and safety of treatment of chronic venous
ulcers with topical timolol.
24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG [Completed]
A crossover, randomized, single-masked study which compares the short-term (3 months)
24-hour IOP control and safety of travoprost/timolol fixed combination given once in the
evening, versus that of latanoprost/timolol fixed combination given once in the evening in
patients with exfoliative glaucoma. The primary objective of this trial is to compare the
quality of 24-hour IOP control after 3 months of chronic therapy with these two medications.
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects [Completed]
Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive
therapy to Xalatan in subjects with glaucoma or ocular hypertension.
Reports of Suspected Betimol (Timolol Ophthalmic) Side Effects
Drug Ineffective (4),
Myasthenia Gravis Crisis (1),
Poor Quality Sleep (1),